Bank Of New York Mellon Corp Otonomy, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.72 - $2.51 $1,878 - $2,740	-1,092 Reduced 1.41%	76,595 $159,000
Q2 2021 Aug 11, 2021	SELL	$2.06 - $2.67 $6,375 - $8,263	-3,095 Reduced 3.83%	77,687 $173,000
Q1 2021 May 13, 2021	SELL	$2.49 - $6.23 $11,264 - $28,184	-4,524 Reduced 5.3%	80,782 $205,000
Q4 2020 Feb 09, 2021	BUY	$3.48 - $6.47 $149,323 - $277,621	42,909 Added 101.21%	85,306 $551,000
Q1 2020 May 06, 2020	SELL	$1.58 - $4.06 $483 - $1,242	-306 Reduced 0.72%	42,397 $83,000
Q1 2019 May 14, 2019	SELL	$1.8 - $2.97 $2,629 - $4,339	-1,461 Reduced 3.31%	42,703 $112,000
Q4 2018 Feb 11, 2019	SELL	$1.51 - $2.93 $680,461 - $1.32 Million	-450,637 Reduced 91.07%	44,164 $82,000
Q3 2018 Nov 09, 2018	SELL	$2.6 - $3.95 $5,548 - $8,429	-2,134 Reduced 0.43%	494,801 $0
Q2 2018 Aug 06, 2018	SELL	$3.7 - $4.75 $396,510 - $509,033	-107,165 Reduced 17.74%	496,935 $1.91 Million
Q1 2018 May 15, 2018	SELL	$4.05 - $6.1 $125,793 - $189,466	-31,060 Reduced 4.89%	604,100 $2.54 Million
Q4 2017 Feb 09, 2018	BUY	$2.8 - $5.55 $1.78 Million - $3.53 Million	635,160	635,160 $3.52 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.